Emergent BioSolutions (EBS) Share-based Compensation (2010 - 2026)
Emergent BioSolutions (EBS) posted quarterly Share-based Compensation of $1.9 million for Q1 2026, up 280.0% year-over-year from $500000.0 in Q1 2025, and up 290.0% quarter-over-quarter from -$1.0 million in Q4 2025.
Emergent BioSolutions (EBS) Share-based Compensation (2010 - 2026) Analysis & Trends
Emergent BioSolutions' Share-based Compensation history runs 17 years deep, the most recent figure standing at $1.9 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 280.0% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.4 million (down 88.89% YoY), while the FY2024 annual figure was $18.0 million, down 22.08% from the prior year.
- Share-based Compensation for Q1 2026 stood at $1.9 million, up from -$1.0 million in the prior quarter.
- The five-year high for Share-based Compensation was $20.7 million in Q4 2023, with the low at -$16.5 million in Q3 2022.
- The 5-year median for Share-based Compensation is $2.1 million (2023), against an average of $2.5 million.
- Peak annual rise in Share-based Compensation reached 2050.0% in 2022, while the deepest fall reached 185.49% in 2022.
- Emergent BioSolutions' Share-based Compensation stood at -$5.7 million in 2022, then soared by 463.16% to $20.7 million in 2023, then plunged by 50.24% to $10.3 million in 2024, then tumbled by 109.71% to -$1.0 million in 2025, then jumped by 290.0% to $1.9 million in 2026.
- Business Quant data shows EBS's Share-based Compensation at $1.9 million in Q1 2026, -$1.0 million in Q4 2025, and -$5.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Emergent BioSolutions | 251.81 Mn | 110.91 Mn | 137.20 Mn | 6.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.00 Mn |
| Jun 30, 2026 | 6.00 Mn |
| Mar 31, 2026 | 1.90 Mn |
| Mar 31, 2026 | 1.90 Mn |
| Dec 31, 2025 | -1.00 Mn |
| Dec 31, 2025 | -1.00 Mn |
| Sep 30, 2025 | -5.10 Mn |
| Sep 30, 2025 | -5.10 Mn |
| Jun 30, 2025 | 5.60 Mn |
| Jun 30, 2025 | 5.60 Mn |
| Mar 31, 2025 | 500,000.00 |
| Mar 31, 2025 | 500,000.00 |
| Dec 31, 2024 | 10.30 Mn |
| Dec 31, 2024 | 10.30 Mn |
| Sep 30, 2024 | -3.70 Mn |
| Sep 30, 2024 | -3.70 Mn |
| Jun 30, 2024 | 5.50 Mn |
| Jun 30, 2024 | 5.50 Mn |
| Mar 31, 2024 | 5.90 Mn |
| Mar 31, 2024 | 5.90 Mn |